XTNT — Stock Film
STOCK FILMSCENE 1/11XTNT · $0.33
Stock Expert AI presents
XTNT
Xtant Medical Holdings, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Xtant Medical Holdings, Inc. A quick introduction.

On the stock market since 2010, it operates in the world of health and science. It has 151 employees. Now — the numbers.

on the stock market since 2010
151 employees
$42.8M market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $4 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 4%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
54%Orthobiologics
Orthobiologics 54%Spinal Implant 32%License Revenue 14%
54% of all revenue comes from a single line: Orthobiologics.

The biggest line carries real weight, but it doesn’t decide everything on its own.

THE SALES TREND
Sales are growing, year after year.

Average growth of 25% a year over the last 4 years. Red columns mark years that ended in a loss.

$55.3M
2021
$58M
2022
$91.3M
2023
$117.3M
2024
$133.9M
2025
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
71
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
52
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
72
strong

Clearly above the class average — a step short of the very top.

GROWTH
82
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
18
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
WEAK SPOTS
The stock has lost its spark0/10
THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 77% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 32% a year on average.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 12 buys and 4 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $1.50361% above today’s price.

1
THE RISKS · 1/2
Trading under $1

The stock sits at $0.33. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

2
THE RISKS · 2/2
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 18/100. For a turnaround signal, the stock first needs to close the gap with the market.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, XTNT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: XTNT is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film